On this page
Neuroferritinopathy
This condition primarily affects adults, causing involuntary movements, problems with balance and coordination, and cognitive changes. It is caused by genetic changes in the FTL gene and typically follows an autosomal dominant inheritance pattern.
Overview
Neuroferritinopathy is a very rare inherited condition that gradually affects the brain and nervous system. It is one of a group of disorders known as Neurodegeneration with Brain Iron Accumulation (NBIA) [PMID:33659265]. The condition causes iron to build up abnormally in certain parts of the brain, which can lead to damage and a range of neurological problems. Symptoms usually begin in adulthood and worsen over time.
This progressive disorder is caused by changes in a gene responsible for producing a protein involved in iron storage. The accumulation of iron in brain cells, particularly in areas important for movement control, is thought to be central to the development of symptoms. Due to its rarity, understanding of the condition continues to evolve through ongoing research efforts.
Symptoms & clinical features
The symptoms of Neuroferritinopathy typically start between the ages of 20 and 60, though onset can vary [PMID:20301389]. Early signs often include involuntary movements, such as chorea (sudden, jerky movements) or dystonia (sustained muscle contractions causing twisting or repetitive movements). Individuals may also experience difficulties with coordination and balance, affecting walking and fine motor skills.
As the condition progresses, other neurological features can emerge. These may include speech difficulties (dysarthria), swallowing problems (dysphagia), and changes in thinking abilities, including memory and executive function. Psychiatric symptoms like depression and personality changes have also been observed in some individuals [PMID:20301389]. The specific combination and severity of symptoms can differ among affected individuals, even within the same family.
Video: Genetics 101
Affected organs
The primary organ affected in Neuroferritinopathy is the brain, particularly areas responsible for motor control and cognitive function. Iron accumulates in specific brain regions, including the basal ganglia, which plays a crucial role in regulating movement. This iron deposition is a hallmark of the condition and is visible on specialised brain imaging techniques.
While the brain is the main focus, other systems may be indirectly affected due to neurological impairment. For instance, muscle function can be impacted by the brain's inability to send proper signals, leading to muscle weakness or stiffness. There is no evidence suggesting widespread iron accumulation in organs outside the central nervous system.
Risks & severity
Neuroferritinopathy is a progressive disorder, meaning its symptoms typically worsen over time. The rate of progression can vary between individuals. The age of symptom onset also shows variability, ranging from early adulthood to later life. While early onset may sometimes correlate with a faster progression, this is not a universal rule.
As a rare disease, the exact prevalence of Neuroferritinopathy is not well established. The severity of the condition can range from mild motor difficulties to severe neurological impairment affecting an individual's independence and quality of life. There is currently no cure, and management focuses on addressing symptoms to improve comfort and function.
Genetic causes
Neuroferritinopathy is caused by pathogenic variants in the FTL gene. The FTL gene provides instructions for making the ferritin light chain protein, which is a component of ferritin. Ferritin is a protein complex that plays a vital role in storing and releasing iron within cells in a controlled manner.
Pathogenic changes in FTL lead to the production of an abnormal ferritin light chain protein. This altered protein is less effective at storing iron and can form insoluble aggregates. These aggregates disrupt normal iron metabolism and lead to the abnormal accumulation of iron within brain cells, ultimately causing cellular damage and the neurological symptoms characteristic of Neuroferritinopathy [PMID:18408107].
- FTL ferritin light chain
Inheritance pattern
Neuroferritinopathy typically follows an autosomal dominant pattern of inheritance. This means that a person only needs to inherit one altered copy of the FTL gene from either parent to develop the condition. If one parent has Neuroferritinopathy, there is a 50% chance with each pregnancy that their child will inherit the altered gene and therefore be at risk of developing the condition.
Autosomal dominant conditions affect both males and females equally. It is also possible for a new, spontaneous genetic change (de novo variant) to occur in the FTL gene, meaning the affected individual is the first in their family to have the condition. Genetic counselling can provide detailed information and support for families concerned about inheritance patterns and risk.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
A diagnosis of Neuroferritinopathy is often suspected based on an individual's characteristic neurological symptoms, particularly the presence of involuntary movements and cognitive changes, combined with a family history consistent with autosomal dominant inheritance. Brain imaging, such as an MRI scan, can show evidence of iron accumulation in specific areas of the brain, which strongly supports a diagnosis.
Confirmation of Neuroferritinopathy relies on genetic testing to identify a pathogenic variant in the FTL gene. Such testing is usually coordinated through clinical genetics services within the NHS. A referral to clinical genetics would typically be made by a neurologist or other specialist. Genetic testing for Neuroferritinopathy falls under the NHS National Genomic Test Directory, and relevant R-codes would be used for referral and testing pathways.
Management & lifestyle
Currently, there is no specific cure for Neuroferritinopathy, so management focuses on addressing symptoms and improving quality of life. This often involves a multidisciplinary approach tailored to the individual's specific needs. For motor symptoms such as chorea or dystonia, medications commonly used for other movement disorders may be prescribed to help reduce their severity.
Supportive therapies are also crucial. Physiotherapy can help maintain mobility and balance, while occupational therapy can assist with daily living activities. Speech and language therapy may be beneficial for speech and swallowing difficulties. Psychological support and counselling can help individuals and families cope with the challenges of a progressive neurological condition. Regular follow-up with a neurologist is important to monitor symptom progression and adjust management strategies as needed. Genetic counsellors can provide further information about the condition, its inheritance, and implications for family planning.
UK care pathway
In the UK, individuals suspected of having a rare genetic condition like Neuroferritinopathy would typically be referred by their GP or a specialist (e.g., a neurologist) to a regional Clinical Genetics service. This service provides expert assessment, genetic counselling, and access to genetic testing as per the NHS Genomic Medicine Service (GMS) pathways. Testing for Neuroferritinopathy would be guided by the NHS National Genomic Test Directory, utilising specific R-codes for gene panel testing (e.g., for NBIA conditions).
Genetic counsellors play a key role in explaining the condition, inheritance patterns, and the implications of a genetic diagnosis for the individual and their wider family. They also help navigate the testing process and provide ongoing support. Multidisciplinary teams, including neurologists, physiotherapists, and speech and language therapists, often work together to provide comprehensive care.
Frequently asked questions
What does 'autosomal dominant' inheritance mean?
Autosomal dominant inheritance means that a person only needs one altered copy of the FTL gene to develop Neuroferritinopathy. If an affected parent has a child, there is a 50% chance that child will inherit the altered gene and could develop the condition.
When do symptoms of Neuroferritinopathy typically start?
Symptoms of Neuroferritinopathy most commonly begin in adulthood, typically between the ages of 20 and 60, though there can be some variation in the age of onset.
Is there a cure for Neuroferritinopathy?
Currently, there is no specific cure for Neuroferritinopathy. Treatment focuses on managing the symptoms to improve the individual's comfort and quality of life through medication and supportive therapies.
How is Neuroferritinopathy diagnosed?
Diagnosis involves a clinical assessment of symptoms, brain MRI scans to look for iron accumulation, and confirmation through genetic testing for pathogenic variants in the FTL gene. This testing is typically arranged by clinical genetics services.
Can children inherit Neuroferritinopathy from an affected parent?
Yes, because Neuroferritinopathy is an autosomal dominant condition, a child has a 50% chance of inheriting the altered gene from an affected parent and being at risk of developing the condition.
References
- Schipper DA, Schipper HM. Neurodegeneration with Brain Iron Accumulation. Advances in experimental medicine and biology. 2025. PMID: 40603798
- Adam MP, Bick S, Mirzaa GM. Neuroferritinopathy. 1993. PMID: 20301320
- Keogh MJ, Morris CM, Chinnery PF. Neuroferritinopathy. International review of neurobiology. 2013. PMID: 24209436
- Yévenes A. The Ferritin Superfamily. Sub-cellular biochemistry. 2017. PMID: 28271473
- Cozzi A, Santambrogio P, Ripamonti M. Pathogenic mechanism and modeling of neuroferritinopathy. Cellular and molecular life sciences : CMLS. 2021. PMID: 33439270
- Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity. The Israel Medical Association journal : IMAJ. 2008. PMID: 18300583
- Lehn A, Boyle R, Brown H. Neuroferritinopathy. Parkinsonism & related disorders. 2012. PMID: 22818529
- Schneider SA, Bhatia KP. Huntington's disease look-alikes. Handbook of clinical neurology. 2011. PMID: 21496572